Frank Laukien: Yes. Sometimes, we see – we have the effect of currencies for people in some of the currencies that have been weakening, like the yen, so China a little bit, right. And Israel most recently have budgeted for our instruments. And then just before they are about to buy their currency drops some percent. But that’s not a brand-new trend. So, we always wrestle with that, and we try to figure it out with the customers, but it’s not really a recent trend. It’s just one of the things we deal with from time-to-time. I haven’t seen any portfolio inflection points or so. I have not seen any, I mean our – we actually had pretty good price realization. We didn’t talk about that much. So, price realization was behind inflation previously.
We are now sort of where price realization at least keeps up with inflation and maybe even turn slightly positive. So, our pricing power has remained very solid, and our competitiveness has remained solid. So again, they will need to update the question anyway. But the answer – the short answer would be no. We haven’t really seen any portfolio inflection points or something or excessive price or significant price sensitivity. I mean price is always important. But ultimately, what’s the best performance or what gives you the research or the results that you need. There are some industries semiconductor, they will buy the best that works for them basis $1 billion fab. It depends on it, and that’s what you guys – the high end of proteomics is, most of the funding is going.
People want the best as opposed to lower – not a lot of lower-end proteomic sales right now, for example.
Dan Arias: Okay. That’s helpful, just figured out that. If I could – Frank, if I could just sneak – can I just sneak one more in on Berkeley Lights, if I may. Those guys had some plans for some additions in the portfolio, just in terms of lower-cost instruments and some application-specific stuff. Does your plan call for carrying forward that roadmap of theirs?
Frank Laukien: Maybe early to say. But Mark, would you like to comment or defer until next year?
Mark Munch: No, we can comment on it. So, that’s correct, for example, the Beacon platform, they had launched some lower-priced position products in terms of the Beacon Quest and Beacon Select in 2023 and those will continue onward. And then kind of – and what that’s about, by the way, is helping expand to new segments, new markets. So, all of that – those kind of trends will continue.
Dan Arias: Okay. Thank you, guys.
Operator: Thank you. I would now like to pass the conference back over to the management team.
Justin Ward: Thank you everyone for joining us today. I do want to note Bruker’s CFO, Gerald Herman, will be presenting at the Jefferies Conference in London on November 14. And Bruker’s leadership team looks forward to meeting with you at an event or speaking with you directly during the fourth quarter. Please feel free to reach out to me to arrange any follow-ups, and have a great day.
Operator: That concludes today’s conference call. Thank you for your participation. You may now disconnect your lines.
